Why I think the NIB share price is a top long-term buy today

This looks like a healthy opportunity to me.

| More on:
A doctor appears shocked as he looks through binoculars on a blue background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price looks like an attractive long-term investment opportunity to me.

I don't mind short-term volatility with a company like this one because the ASX healthcare share is an effective way to play a strong investment trend, in my view.

It can be tricky to find investment ideas that can truly play the healthcare theme because some companies only 'tap' one area of the sector. Certain treatments or technology may be challenged by a competitor. For example, just look at the pain being suffered by CSL Limited (ASX: CSL) and Resmed (ASX: RMD) amid the rise of 'weight loss' drugs like Ozempic.

Here are the three main reasons I think now is a good time to invest at the current NIB share price.

Broad exposure to the health industry

I believe NIB is an effective way to access healthcare (spending) exposure because it's used for a wide variety of healthcare reasons, and it can generate earnings from people when they're not spending as well. Additionally, people earning above a certain income are 'encouraged' to get private health insurance just to avoid the Australian Tax Office's Medicare levy surcharge.

In my opinion, NIB is an effective 'picks and shovels' choice. What does that mean? In the olden days, people would try to find a commodity such as gold. If they found gold, they could be rich, but equally, they might not find anything at all.

However, the people selling picks and shovels to those miners would gain business and make money, whatever the outcome. It wasn't a high-risk industry, but it was a play on the gold rush.

Health spending is expected to keep rising (including as a percentage of GDP) for many years to come, and I believe healthcare insurance is an effective way to ride that trend. It doesn't require the business to 'strike gold' on a treatment or continue having the best health-related device.

It seems like a smart move by the business to expand in areas that are similar to what NIB currently offers and where spending could rise, such as NDIS businesses and travel insurance.

Population growth helps

I like investments that benefit from population growth. Whether we agree or not with the large annual increases in Australia's population, there are some industries that are clear beneficiaries.

The bigger the Australian population, the more likely it is that the NIB's Australian Resident Health Insurance (ARHI) membership can keep growing and boost earnings.

In FY23, the NIB ARHI membership increased by 4.7%, which is the strongest result since FY15 and more than double the anticipated industry growth. This will likely support the NIB share price.

In addition, the company is benefiting from an influx of international workers following the end of COVID-19 border closures. In FY23, international inbound health insurance saw policyholder and premium growth of 15.7% and 22.4%, respectively.

Increasing scale can help the business deliver stronger earnings over time, in my opinion. In FY23, the NIB underlying operating profit increased by 11.1% to $263.2 million.

Valuation and dividend

Since 21 June 2023, the NIB share price has declined by almost 20%, making it quite a bit cheaper than it used to be.

According to the earnings forecast on Commsec, the company is valued at 17x FY24's estimated earnings and less than 16x FY25's estimated earnings. I don't think this is a demanding price/earnings (P/E) ratio for a long-term growth business.

The dividend is projected to keep growing. In FY24, the grossed-up dividend yield could be 5.6%, and in FY25, the grossed-up dividend yield could be 6%. The rising dividend can help shareholder returns, which is another positive factor.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »